<?xml version='1.0' encoding='utf-8'?>
<document id="23307267"><sentence text="Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes."><entity charOffset="10-19" id="DDI-PubMed.23307267.s1.e0" text="voglibose" /><entity charOffset="47-60" id="DDI-PubMed.23307267.s1.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.23307267.s1.e0" e2="DDI-PubMed.23307267.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s1.e0" e2="DDI-PubMed.23307267.s1.e1" /></sentence><sentence text="Dapagliflozin is an orally administered selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM)"><entity charOffset="0-13" id="DDI-PubMed.23307267.s2.e0" text="Dapagliflozin" /><entity charOffset="57-64" id="DDI-PubMed.23307267.s2.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23307267.s2.e0" e2="DDI-PubMed.23307267.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s2.e0" e2="DDI-PubMed.23307267.s2.e1" /></sentence><sentence text=" Dapagliflozin lowers blood glucose through a reduction in renal glucose reabsorption"><entity charOffset="1-14" id="DDI-PubMed.23307267.s3.e0" text="Dapagliflozin" /><entity charOffset="28-35" id="DDI-PubMed.23307267.s3.e1" text="glucose" /><entity charOffset="65-72" id="DDI-PubMed.23307267.s3.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.23307267.s3.e0" e2="DDI-PubMed.23307267.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s3.e0" e2="DDI-PubMed.23307267.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23307267.s3.e0" e2="DDI-PubMed.23307267.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23307267.s3.e1" e2="DDI-PubMed.23307267.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23307267.s3.e1" e2="DDI-PubMed.23307267.s3.e2" /></sentence><sentence text=" This study was performed to assess the effect of the oral antidiabetic agent voglibose [0"><entity charOffset="78-87" id="DDI-PubMed.23307267.s4.e0" text="voglibose" /></sentence><sentence text="2 mg thrice daily (t" /><sentence text="i" /><sentence text="d" /><sentence text=")] at steady-state, on the pharmacokinetics, safety and tolerability of dapagliflozin administered as a single oral dose (10 mg) to Japanese patients with T2DM"><entity charOffset="72-85" id="DDI-PubMed.23307267.s8.e0" text="dapagliflozin" /></sentence><sentence text="" /><sentence text="This was an open-label, multi-center, drug-drug interaction study" /><sentence text=" A single oral dose of dapagliflozin (10 mg) was administered to 22 Japanese patients with T2DM in the presence and absence of voglibose (0"><entity charOffset="23-36" id="DDI-PubMed.23307267.s11.e0" text="dapagliflozin" /><entity charOffset="127-136" id="DDI-PubMed.23307267.s11.e1" text="voglibose" /><pair ddi="false" e1="DDI-PubMed.23307267.s11.e0" e2="DDI-PubMed.23307267.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s11.e0" e2="DDI-PubMed.23307267.s11.e1" /></sentence><sentence text="2 mg t" /><sentence text="i" /><sentence text="d" /><sentence text=")" /><sentence text=" Serial blood samples were collected before and at regular prespecified intervals after each dapagliflozin dose to determine dapagliflozin plasma concentrations and to evaluate pharmacokinetic parameters"><entity charOffset="93-106" id="DDI-PubMed.23307267.s16.e0" text="dapagliflozin" /><entity charOffset="125-138" id="DDI-PubMed.23307267.s16.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.23307267.s16.e0" e2="DDI-PubMed.23307267.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s16.e0" e2="DDI-PubMed.23307267.s16.e1" /></sentence><sentence text=" Based on a mixed effect analysis of variance model, including the dosing condition as a fixed effect and patients as a random effect, the ratios of geometric means of area under curve from time 0 to infinity (AUC0-inf) and maximum observed plasma concentration (C max) with and without voglibose were estimated along with two-sided 90% confidence intervals (CIs)"><entity charOffset="287-296" id="DDI-PubMed.23307267.s17.e0" text="voglibose" /></sentence><sentence text="" /><sentence text="In Japanese patients with T2DM, the exposure to dapagliflozin following a single oral dose of dapagliflozin 10 mg was not influenced by the concomitant administration of voglibose (0"><entity charOffset="48-61" id="DDI-PubMed.23307267.s19.e0" text="dapagliflozin" /><entity charOffset="94-107" id="DDI-PubMed.23307267.s19.e1" text="dapagliflozin" /><entity charOffset="170-179" id="DDI-PubMed.23307267.s19.e2" text="voglibose" /><pair ddi="false" e1="DDI-PubMed.23307267.s19.e0" e2="DDI-PubMed.23307267.s19.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s19.e0" e2="DDI-PubMed.23307267.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23307267.s19.e0" e2="DDI-PubMed.23307267.s19.e2" /><pair ddi="false" e1="DDI-PubMed.23307267.s19.e1" e2="DDI-PubMed.23307267.s19.e1" /><pair ddi="false" e1="DDI-PubMed.23307267.s19.e1" e2="DDI-PubMed.23307267.s19.e2" /></sentence><sentence text="2 mg t" /><sentence text="i" /><sentence text="d" /><sentence text=")" /><sentence text=" The geometric ratio (90% CI) for dapagliflozin AUC0-inf with/without voglibose was 1"><entity charOffset="34-47" id="DDI-PubMed.23307267.s24.e0" text="dapagliflozin" /><entity charOffset="70-79" id="DDI-PubMed.23307267.s24.e1" text="voglibose" /><pair ddi="false" e1="DDI-PubMed.23307267.s24.e0" e2="DDI-PubMed.23307267.s24.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s24.e0" e2="DDI-PubMed.23307267.s24.e1" /></sentence><sentence text="009 (0" /><sentence text="954, 1" /><sentence text="067), and for C max 1" /><sentence text="040 (0" /><sentence text="899, 1" /><sentence text="204)" /><sentence text=" The median time to C max (t max) and plasma clearance of dapagliflozin were also similar between treatments"><entity charOffset="58-71" id="DDI-PubMed.23307267.s31.e0" text="dapagliflozin" /></sentence><sentence text=" The mean half-life (t ½) for dapagliflozin was slightly higher when administered in combination with voglibose"><entity charOffset="30-43" id="DDI-PubMed.23307267.s32.e0" text="dapagliflozin" /><entity charOffset="102-111" id="DDI-PubMed.23307267.s32.e1" text="voglibose" /><pair ddi="false" e1="DDI-PubMed.23307267.s32.e0" e2="DDI-PubMed.23307267.s32.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s32.e0" e2="DDI-PubMed.23307267.s32.e1" /></sentence><sentence text=" Dapagliflozin 10 mg was well tolerated when administered alone and in combination with voglibose in Japanese patients with T2DM"><entity charOffset="1-14" id="DDI-PubMed.23307267.s33.e0" text="Dapagliflozin" /><entity charOffset="88-97" id="DDI-PubMed.23307267.s33.e1" text="voglibose" /><pair ddi="false" e1="DDI-PubMed.23307267.s33.e0" e2="DDI-PubMed.23307267.s33.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s33.e0" e2="DDI-PubMed.23307267.s33.e1" /></sentence><sentence text="" /><sentence text="The results presented here support the co-administration of dapagliflozin and voglibose without dose adjustment of either agent"><entity charOffset="60-73" id="DDI-PubMed.23307267.s35.e0" text="dapagliflozin" /><entity charOffset="78-87" id="DDI-PubMed.23307267.s35.e1" text="voglibose" /><pair ddi="false" e1="DDI-PubMed.23307267.s35.e0" e2="DDI-PubMed.23307267.s35.e0" /><pair ddi="false" e1="DDI-PubMed.23307267.s35.e0" e2="DDI-PubMed.23307267.s35.e1" /></sentence><sentence text="" /></document>